Cerebral Cavernous Malformations 3 (CCM3) Cell Models for Research

Cerebral Cavernous Malformations (CCM) are vascular malformations of the central nervous system, affecting approximately 0.5% of the population. CCM3, caused by mutations in the PDCD10 gene, is the most aggressive form, with a higher risk of hemorrhage and neurological deficits. The exact incidence of CCM3 is not well-defined, but it accounts for about 10-15% of familial CCM cases. The clinical impact is significant: patients often experience seizures, headaches, and focal neurological deficits. The 5-year risk of hemorrhage for CCM3 is estimated to be higher than for other CCM subtypes, though precise data are limited. According to the National Cancer Institute (NCI), there is no specific survival data for CCM3 as it is not a cancer; however, the morbidity is substantial. Key risk factors include genetic predisposition (autosomal dominant inheritance) and the presence of multiple lesions. Research into CCM3 is crucial to understand the molecular mechanisms and develop targeted therapies.

CCM3 is an ideal model for studying vascular development and disease due to its well-defined genetic basis and the availability of robust in vitro and in vivo models. The disease is caused by loss-of-function mutations in PDCD10, which encodes a scaffold protein involved in multiple signaling pathways. This makes it a valuable target for functional genomics and drug discovery. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project and the Cancer Genome Atlas (TCGA), provide expression data for PDCD10 across tissues, facilitating research. Open questions include the precise role of PDCD10 in endothelial cell signaling, the mechanisms of lesion formation, and the development of targeted therapies. Gene-edited cell models, such as PDCD10 knockout endothelial cells, are essential for addressing these questions.

CCM3 is not a cancer, but it shares some signaling pathways with cancer. The major pathways involved in CCM3 pathogenesis include:

• • MAPK/ERK Pathway: PDCD10 regulates the MAPK pathway, which is involved in cell proliferation and differentiation. Loss of PDCD10 leads to hyperactivation of this pathway, contributing to endothelial cell dysfunction.
• • PI3K/AKT Pathway: PDCD10 interacts with the PI3K/AKT pathway, which is critical for cell survival and angiogenesis. Dysregulation of this pathway promotes abnormal vascular growth.
• • Wnt/β-Catenin Pathway: PDCD10 modulates Wnt signaling, which is essential for vascular development. Mutations in PDCD10 can disrupt this pathway, leading to malformations.
• • RhoA/ROCK Pathway: PDCD10 regulates RhoA activity, which controls cytoskeletal dynamics and cell migration. Loss of PDCD10 results in increased RhoA activity, contributing to endothelial barrier dysfunction.

Data from ClinVar and COSMIC indicate that PDCD10 mutations are predominantly inactivating. The frequency of PDCD10 mutations in sporadic CCM is lower, but they are still significant.

The loss of PDCD10 disrupts several signaling networks:

• • MAPK/ERK: Hyperactivation leads to increased cell proliferation.
• • PI3K/AKT: Enhanced survival signals promote abnormal vessel formation.
• • Wnt/β-catenin: Altered signaling affects cell fate and vascular patterning.
• • RhoA/ROCK: Increased activity causes cytoskeletal changes and endothelial barrier dysfunction.

These networks are interconnected, and their dysregulation contributes to the formation of cavernous malformations.

Organoids derived from patient iPSCs can also be used to model CCM3, providing a more physiologically relevant 3D environment. However, gene-edited cell lines offer a more controlled and reproducible system for mechanistic studies.

• • Genetically Engineered Mouse Models (GEMM): Conditional knockout of Pdcd10 in endothelial cells (e.g., using Cre-lox systems) recapitulates CCM lesions.
• • Induced Models: Injection of adeno-associated viruses (AAV) expressing Cre recombinase into mice with floxed Pdcd10 alleles induces lesions.
• • Patient-Derived Xenografts (PDX): Not commonly used for CCM, but can be used to study the effects of specific mutations in vivo.

CRISPR-Cas9 gene editing allows the creation of isogenic cell lines with precise mutations in PDCD10. For example, a PDCD10 knockout HUVEC line can be generated by introducing a frameshift mutation in exon 3. Alternatively, a knock-in line with a specific point mutation (e.g., R101X) can be created to model a patient-specific mutation. These models are commercially available from various sources and are sequence-verified to ensure accuracy. They are essential for studying the functional consequences of PDCD10 loss and for drug screening.

Gene-edited cell lines are used to validate the role of PDCD10 in signaling pathways. For example, PDCD10 knockout cells can be used to assess the effect on MAPK/ERK activation by Western blotting. Additionally, rescue experiments with wild-type PDCD10 can confirm specificity. These models are also used in CRISPR screens to identify synthetic lethal partners or downstream effectors.

Isogenic pairs (wild-type vs. PDCD10 knockout) are ideal for high-throughput screening of compounds that selectively target CCM3-deficient cells. This can lead to the discovery of drugs that prevent lesion formation or progression. Resistance mechanisms can also be studied by exposing cells to drugs and selecting for resistant clones.

CRISPR-based synthetic lethality screens can identify genes that are essential in PDCD10-deficient cells but not in wild-type cells. These genes may serve as biomarkers or therapeutic targets. For example, a screen might reveal that certain kinases are upregulated in knockout cells, providing potential targets for intervention.